

Name of the Issue: STAR HEALTH AND ALLIED INSURANCE COMPANY LIMITED

1 Type of Issue Initial Public Offer

2 Issue Size (Rs. Mn) 64,004.39

Source: Prospectus

3 Grade of issue along with name of the rating agency

Name NA

Grade NA

4 Subscription Level (Number of times) 0.95

Source: Basis of allotment

5 QIB Holding (as a % of Outstanding Capital) as disclosed to the stock exchanges

Particulars	%
(i) On Allotment *	37.18%
(ii) at the end of the 1st Quarter immediately after the listing of the issue (December 31, 2021)**	37.35%
(iii) at the end of 1st FY (March 31, 2022)**	N.A.
(iv) at the end of 2nd FY (March 31, 2023)**	N.A.
(v) at the end of 3rd FY (March 31, 2024)**	N.A.

*Shareholding pattern disclosed to Stock Exchanges

** QIB Holding not disclosed as reporting for relevant period has not been completed.

6 Financials of the issuer

(Rs. Million)

Parameters	1st FY (March 31, 2022) *	2nd FY (March 31, 2023) *	3rd FY (March 31, 2024) *
Income from operations	Not Available	Not Available	Not Available
Net Profit for the period	Not Available	Not Available	Not Available
Paid-up equity share capital	Not Available	Not Available	Not Available
Reserves excluding revaluation reserves	Not Available	Not Available	Not Available

* Financials not available as reporting for the relevant years has not been completed.

7 Trading Status

The equity shares of the Company are listed on BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE")

The equity shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2022) *	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2023) *	Not Available
(iii) at the end of 3rd FY (March 31, 2024) *	Not Available

* Trading status not disclosed as the relevant fiscal years have not been completed.

Source: Stock exchange data.

8 Change in Directors of Issuer from the disclosures in the offer document

Particulars	Name of Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2022) *	Not Available	Not Available
(ii) at the end of 2nd FY (March 31, 2023) *	Not Available	Not Available
(iii) at the end of 3rd FY (March 31, 2024) *	Not Available	Not Available

* Changes in Directors of Issuer not updated as the relevant financial years have not been completed

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

10 Status of utilization of issue proceeds

(i) As disclosed in the offer document	20,000 million
(ii) Actual utilization	Presently no proceeds have been utilised
(iii) Reasons for deviation, if any	Not applicable

11 Comments of monitoring agency, if applicable

(i) Comments on use of funds	Not applicable
(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document	Not applicable
(iii) Any other reservations expressed by the monitoring agency about the end use of funds	Not applicable

12 Pricing Data

Designated Stock Exchange	BSE
Issue Price (Rs.)	900.00
Listing Date	10-Dec-21

Price parameters	At close of listing day- 10-Dec-2021	Close of 30th calendar day from listing day (10-Jan-2022)*	Close of 90th calendar day from listing day *	As at the end of the 1st FY after the listing of the issue (31st March, 2022)*		
				Closing price	High	Low
Market Price	906.85	Not Available	Not Available	Not Available	Not Available	Not Available
Nifty	17,511.30	Not Available	Not Available	Not Available	Not Available	Not Available
Price parameters	As at the end of the 2nd FY after the listing of the issue (31st March, 2023)*			As at the end of the 3rd FY after the listing of the issue (31st March, 2024)*		
	Closing price	High	Low	Closing price	High	Low
Market Price	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Nifty	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available

* The pricing data is not disclosed as the relevant fiscal years have not been completed

13 Basis for Issue Price

Accounting ratio		As disclosed in	At the end of 1st	At the end of	At the end of
		offer	FY (March 31,	1st FY (March	1st FY (March
		document, at	2022)**	31, 2023)**	31, 2024)**
		the end of FY			
		2021*			
EPS (Basic & Diluted)	Company				
	Standalone	-16.54	Not Available	Not Available	Not Available
	Peer Group & Industry Avg	21.18	Not Available	Not Available	Not Available
	ICICI Lombard General Insurance Company Ltd.	32.41	Not Available	Not Available	Not Available
	New India Assurance Company Limited	9.95	Not Available	Not Available	Not Available
P/E	Company				
	Standalone	Not meaningful	Not Available	Not Available	Not Available
	Peer Group & Industry Avg[^]	30.98	Not Available	Not Available	Not Available
	ICICI Lombard General Insurance Company Ltd.	46.66	Not Available	Not Available	Not Available
	New India Assurance Company Limited	15.30	Not Available	Not Available	Not Available
RoNW	Company				
	Standalone	-23.69%	Not Available	Not Available	Not Available
	Peer Group & Industry Avg	14.31%	Not Available	Not Available	Not Available
	ICICI Lombard General Insurance Company Ltd.	19.81%	Not Available	Not Available	Not Available
	New India Assurance Company Limited	8.81%	Not Available	Not Available	Not Available
NAV per share	Company				
	Standalone	63.58	Not Available	Not Available	Not Available
	Peer Group & Industry Avg	137.87	Not Available	Not Available	Not Available
	ICICI Lombard General Insurance Company Ltd.	163.56	Not Available	Not Available	Not Available
	New India Assurance Company Limited	112.17	Not Available	Not Available	Not Available

Notes

* Sourced from Prospectus

**Not available as the relevant fiscal years have not been completed / information not disclosed

[^] P/E is calculated as closing market price on NSE as on November 18, 2021/ Basic EPS for the year ended March 31, 2021 sourced from Star health Prospectus

14 Any Material Information

Particulars	Date
Listing of equity shares of Shar Health and Allied Insurance Company Limited	10-dec-21
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011	14-dec-21
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order	21-dec-21
Submission of Report for violation of Code of Conduct under SEBI (Prohibition of Insider Trading) Regulations 2015 ("PIT Regulation")	22-mar-22
Board of Directors of the Company, vide Circular Resolution dated March 4, 2022 had approved the appointment of Mr.V.Jagannathan Whole Time Director & CEO of the Company as the Chairman of the Board with immediate effect i.e. March 4, 2022 until the remainder of his tenure i.e. June 16, 2025	4-mar-22

Note: For further updates and information, please refer Stock Exchange websites